Wisconsin Alumni Research Foundation

Brigham Young University

Tahitian Noni International, Inc.

Benjamin J Darien

Paul B Savage

Richard G Godbee

Compositions and methods for preparing stabilized CSA compositions having reduced agglomeration and increased stability. The compositions have increased efficacy in killing microbes and reduced cytotoxicity to mammals. The compositions include a liquid carrier, micelles formed from an amphiphilic material, and CSA molecules encapsulated by the micelles. The CSA compositions can be formed by blending together a solvent or liquid carrier, a plurality of CSA molecules, and a micelle-forming agent and causing or allowing the micelle-forming agent to form micelles encapsulating at least a portion of the CSA molecules so that no more than 25% of the CSA molecules form agglomerates larger than 1 &#x3bc;m in size. The CSA compositions can be used to treat mammals, such as mammals suffering from microbial diseases or infections.

Compositions and methods for forming stabilized compositions with reduced CSA agglomeration

Both liquid and dry formenhanced animal food products are provided for increasing CD8T cell activation in new born animals. Both containfruit puree and otherplant products.

[object Object]

A novel bovine P-selectin glycoprotein ligand-1 (bPSGL-1) is disclosed having the amino acid sequence set forth in SEQ. ID. NO:. DNA sequences encoding the bPSGL-1 are also disclosed, along with vectors, host cells, and methods of using the bPSGL-1. The invention further provides methods for preventing or reducing acute inflammatory response in a bovine subject by administering bPSGL-1 and fragments thereof (e.g., a bPSGL-1 Ig fusion protein). The invention also provides methods for identifying compounds of reducing or preventing damage to tissue or organs caused by acute inflammatory response in a bovine.

Bovine P-selectin glycorpotein ligand-1

A novel equine P-selectin glycoprotein ligand-1 (ePSGL-1) is disclosed having the amino acid sequence set forth in SEQ ID NO:2. DNA sequences encoding the ePSGL-1 are also disclosed, along with vectors, host cells, and methods of making the ePSGL-1. The invention further provides methods for preventing or reducing acute inflammatory response in an equine subject by administering ePSGL-1 and fragments thereof (e.g., an ePSGL-1-Ig fusion protein). The invention also provides methods for identifying compounds capable of reducing or preventing damage to tissue or organs caused by acute inflammatory response in an equine subject.

Growing community of inventors

Madison, WI, United States of America

Benjamin J Darien